Welcome to our dedicated page for KAZIA THERAPEUTICS SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KAZIA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KAZIA THERAPEUTICS's regulatory disclosures and financial reporting.
Kazia Therapeutics Limited has entered a License and Commercialisation Agreement with QIMR Berghofer, gaining an exclusive worldwide license to develop and commercialize cancer therapies based on a proprietary SETDB1-targeted epigenetic platform.
Kazia will pay an upfront license fee of $1,390,000 and share a percentage of future commercialization revenue, with rates linked to the development stage at which any product is out-licensed. The lead candidate, MSETC, is a highly selective bicyclic peptide discovered using an AI-integrated epigenetic drug discovery engine and is designed to restore immune signaling in tumors resistant to immunotherapy.
The company plans to advance the SETDB1 and PD-L1 degrader programs through IND-enabling studies over about 18 months at a combined expected cost of approximately $6 million, leveraging shared CRO resources and Australian R&D tax incentives. Kazia views the SETDB1 platform as complementary to its existing oncology pipeline, which includes paxalisib and EVT801.
Kazia Therapeutics Ltd chief executive John E. Friend II reports his holdings of an American Depositary Share (ADS) option covering 30,000 ADSs. The ADS option was granted on July 22, 2024 at an exercise price of $18.85 per ADS and expires on July 22, 2027. It vests in equal quarterly installments over three years beginning April 22, 2024, contingent on continued service. This amended Form 3 corrects the exercise price of the previously reported ADS option.
Kazia Therapeutics executive David Cain filed an initial ownership report showing he holds several stock option awards. These include options over 5,000 American Depositary Shares at an exercise price of $19.0000 and 100,000 ADS at $8.0000, plus options over 100,000 and 400,000 Ordinary Shares at exercise prices of $0.6651 and $0.1061. The options vest in scheduled annual or quarterly installments, contingent on his continued service, and expire between February 1, 2027 and July 22, 2027.
Kazia Therapeutics Limited filed a prospectus supplement to update its Form F-1 registration for 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares, referencing a Form 6-K dated March 31, 2026. The supplement attaches a March 27, 2026 investor presentation and fact sheet and notes a board change: Chairman Bryce Carmine resigned effective March 31, 2026, reducing the board from four to three directors. The company reported the re-election of Steven Coffey with 1,050,412,780 votes for.
Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 Ordinary Shares, and furnishes a Form 6-K dated March 31, 2026. The supplement attaches an investor presentation and fact sheet dated March 27, 2026 and notes the ADS last sale price of $7.31 per ADS.
The Form 6-K reports the resignation of Chairman Bryce Carmine effective March 31, 2026, a reduction in Board size from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and shareholder re-election of Steven Coffey at the AGM.
Kazia Therapeutics Limited filed a prospectus supplement updating its Form F-1 registration to reflect a Form 6-K furnished March 31, 2026. The supplement covers 266,666 ADSs representing 133,333,000 Ordinary Shares and states the ADSs trade on Nasdaq under the symbol KZIA. The company reported the March 25, 2026 Annual General Meeting approved the re-election of Steven Coffey with 1,050,412,780 votes for, and noted the resignation of Chairman Bryce Carmine effective March 31, 2026, reducing the Board from four to three directors.
Kazia Therapeutics Limited files a prospectus supplement registering 232,956 American Depositary Shares (ADSs). The supplement attaches a Form 6-K dated March 31, 2026 and updates the Prospectus dated December 23, 2025.
The Form 6-K discloses the resignation of Chairman Bryce Carmine effective March 31, 2026, the Board shrinking from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and AGM vote results re‑electing Steven Coffey (1,050,412,780 for; 3,637,588 against; 1,289,127 abstain). The ADSs trade on Nasdaq under symbol KZIA (last reported sale $7.31 per ADS).
Kazia Therapeutics Limited reports board changes, shareholder voting outcomes, and shares an updated corporate overview. Chairman Bryce Carmine will retire effective March 31, 2026, and the board will shrink from four to three directors, with Ebru Davidson joining the Audit, Risk and Governance Committee. The company states his resignation is not due to any disagreement over operations or policies. Shareholders re-elected director Steven Coffey, with 1,050,412,780 votes for and 3,637,588 against.
Kazia also furnishes a detailed investor presentation and fact sheet outlining its oncology pipeline. Lead asset paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor, has been studied in more than 550 patients and is being advanced in glioblastoma, pediatric brain cancers, brain metastases, and triple negative breast cancer, where early Phase 1b data include one complete metabolic response and two partial responses. The company highlights cash and cash equivalents of about US$46 million, no debt, and an expected cash runway into 2029, as well as a preclinical PD-L1 protein degrader (NDL2) and VEGFR3 inhibitor EVT801.
Kazia Therapeutics Ltd ownership update: A Schedule 13G/A amendment reports that Jorey Chernett beneficially owned 1,588,129 American Depositary Shares as of the close of business on 02/19/2026, representing 13.90% of the class based on 11,426,899 ADS outstanding as of 03/12/2026.
The filing lists sole voting and dispositive power over those ADS and is signed on 03/31/2026.
Kazia Therapeutics Ltd reported that Alumni Capital LP, Alumni Capital GP LLC and Ashkan Mapar hold no American Depository Shares as of January 30, 2026. This Amendment No. 5 Schedule 13G/A functions as an exit filing, showing 0 shares and 0% ownership for each reporting person.
The filing lists the reporting persons' principal business address and confirms the General Partner and controlling person relationships; signatures are dated March 30, 2026.